TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Known prostate cancer with a clinical concern for the presence of metastatic disease as delineated below:~   * Treatment naïve patients with one of the following risk factors: CAPRA (Cancer of the Prostate Risk Assessment) score ≥ 5, Prostate-specific antigen (PSA) ≥ 15 ng/mL and/or Gleason score ≥ 4+4.~  * Patients with biochemical recurrence after prostatectomy or radiation therapy with a PSA doubling time less than 12 months.~     i. These patients may have received androgen deprivation therapy prior to imaging.~  * Patients with castrate resistant prostate cancer with progressive disease as defined by Prostate Cancer Clinical Trials Working Group (PCWG2) criteria (27).~     i. Patients with castrate resistant prostate cancer can be either on treatment or off treatment~2. Age \> 18.~3. Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).~4. Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~1. Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.~2. Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).~3. Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk prostate cancer pre-prostatectomy (preRP) population (Type: EXPERIMENTAL): Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
- Biochemical Recurrence (BCR) (Type: EXPERIMENTAL): Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
- Castrate Resistant Prostate cancer (CRCP) population (Type: EXPERIMENTAL): Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Mental Health Care by Scientifically Matching Patients to Providers' Strengths

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Being 18-70 years of age~* Being the primary, informed decision-maker for one's care~* Willingness to be randomized to condition and to complete a few study-specific measures~Exclusion:~* Being under 18 or over 70 years of age~* Not being responsible for one's own treatment decisions~* Unwillingness to be randomized to condition and/or to complete a few study-specific measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pragmatic Match (Type: NO_INTERVENTION): Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
- Scientific Match (Type: EXPERIMENTAL): Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-75 years who satisfied RomeIII criteria for the diagnosis of IBS~* Signed informed consent~Exclusion Criteria:~* IBS-D~* evidence of cathartic colon or history laxative abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics(Medirac) 10/mosapride 10mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 15/mosapride 10mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 15/mosapride 15mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 30/mosapride 15mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) placebo/mosapride placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs)~* Healthy female subjects and/or male subjects of African-American/Black or Caucasian race~Exclusion Criteria:~* History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males~* Treatment with an investigational drug within 30 days~* Screening supine blood pressure \<90 or \>/=140 mm Hg (systolic) or \<60 or \>/= 90 mm Hg (diastolic), following at least 5 minutes of supine rest~* Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.~* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day~* Subjects who have a CYP3A4\*22 allele and/or have a SLCO1B1 \*5 or \*15 allele

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): African-Americans with No CYP3A5\*1 alleles (poor metabolizer)
- Cohort 2 (Type: EXPERIMENTAL): African-Americans with One CYP3A5\*1 allele (intermediate metabolizer)
- Cohort 3 (Type: EXPERIMENTAL): African-Americans with Two CYP3A5\*1 alleles (extensive metabolizer)
- Cohort 4 (Type: EXPERIMENTAL): Caucasians with No CYP3A5\*1 alleles (poor metabolizer)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Versus Propofol in Vitreoretinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists rating of I-III~* good renal and liver function~Exclusion Criteria:~* renal and hepatic insufficiency~* uncontrolled diabetes~* uncontrolled hypertension~* severe cardiac disease Class III or IV~* heart blocks~* chronic use of sedatives, narcotics, alcohol or illicit drugs~* allergy to either propofol or dexmedetomidine~* pregnancy or inability to tolerate technique of the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
- dexmedetomidine infusion (Type: EXPERIMENTAL): Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery~* Extensive disease (distant disease, pleural disease, pulmonary with or without mediastinal disease, or recurrent progressive disease in site of prior radiotherapy)~* Advanced limited disease allowed if ineligible for primary radiotherapy or surgery~* Measurable disease~* Age 18 and over~* ECOG Performance Status 0-1~* Granulocyte count at least 1,500 cells/mm\^3~* Platelet count at least 100,000 cells/mm\^3~* Bilirubin no greater than 1.5 mg/dL~* Creatinine no greater than 2.0 mg/dL~* Concurrent corticosteroids for myasthenia gravis or other chronic conditions allowed~Exclusion Criteria:~* Acute concurrent complications such as infection or post-surgical complications~* Other prior malignancy within the past 5 years unless curatively treated with no evidence of recurrence~* Pregnant or nursing. A negative pregnancy test was required, and fertile patients must use effective contraception~* Prior chemotherapy for metastatic disease. Prior preoperative or adjuvant chemotherapy allowed if disease-free survival prior to recurrence was more than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel plus Carboplatin (Type: EXPERIMENTAL): Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord that had never been treated with AA4500.~* Had a positive table top test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.~* Judged to be in good health.~Exclusion Criteria:~* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.~* Had received a treatment for Dupuytren's contracture, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.~* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AA4500 0.58 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with FRDA confirmed by genetic testing with 2 expanded Guanine-adenine-adenine repeats~* Females who are not pregnant or breast feeding, and who do not intend to become pregnant. Females of child-bearing potential must use a reliable method of contraception and must provide a negative urine pregnancy test at screening~* Stable doses of all medications, vitamins and supplements for 30 days prior to study entry and for the duration of the study~* Parent/guardian permission (informed consent) and child assent~Exclusion Criteria:~* Any unstable illness that in the investigator's opinion precludes participation in this study~* Use of any investigational product within 30 days prior to enrollment~* Subjects with a history of substance abuse~* Presence of clinically significant cardiac disease~* History of hypersensitivity to IFN-g or E. coli derived products~* Presence of severe renal disease or hepatic disease~* Clinically significant abnormal White blood cell count, hemoglobin or platelet count~* Any subject planning a scheduled surgical procedure during the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Interferon Gamma-1b (ACTIMMUNE) (Type: EXPERIMENTAL): All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Aged \<5 years~2. Weight \>5 kg~3. Suffering from acute uncomplicated P. falciparum malaria confirmed by RDT. Later microscopy using Giemsa-stained thick film will be made to ensure asexual parasite density of 2000 to 200 000 parasites/µL~4. Having a history of fever in the preceding 24 h~5. Able to ingest tablets orally~6. Willing and able to attend stipulated follow-up visits~7. With written informed consent from parent/guardian for children to participate in the trial.~Exclusion Criteria:~Presenting with any of the following danger signs of severe malaria:~1. Convulsions (\>1 episode within previous 24 hours)~2. Lethargic/unconscious

- Gender: ALL
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SERETIDE Plus Tiotropium Versus Individual Components

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has an established clinical history of COPD as defined as per the GOLD definition.~* Post-bronchodilator FEV1 of \>30% to 75% of predicted normal at Visit 1, a post-bronchodilator FEV1 / FVC ratio = 70%.~* Current or ex-smoker with a smoking history of \> 10 pack-years.~Exclusion Criteria:~* Has unstable COPD (Chronic Obstructive Pulmonary Disease).~* Has a current medical diagnosis of asthma and/or allergic rhinitis or know respiratory disorders (lung cancer, sarcoidosis, tuberculosis or lung fibrosis) Requires regular (daily) or long term oxygen therapy (LTOT). (LTOT is defined as \> 12 hours oxygen use per day).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study~* Normal electrocardiogram (ECG) at Screening~* No abnormal finding of clinical relevance (other than NASH, suspected NASH in patients) at Screening that could adversely impact subject safety during the study or adversely impact study results.~Exclusion Criteria:~* Clinically significant health concerns (other than NASH, suspected NASH in patients)~* Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)~* Uncontrolled hypertension~* Excessive use of alcohol within three months prior to Screening~* Use of illicit drugs within 1 year prior to Screening, or positive urine drug screen at Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study~NOTE: additional inclusion/exclusion criteria may apply, per protocol~-~-

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ARO-HSD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status I and II~* weighted 50 kg-65 kg~* aged 40-65 yr~* elective laparoscopic hysterectomy with general anesthesia~Exclusion Criteria:~* a history of allergy to local anesthetics~* severe respiratory, renal or hepatic disease~* preoperative opioids medication~* psychiatric medical history~* Patients with severe hypotension \[mean arterial pressure (MAP\<60 mmHg)\] or bradycardia \[heart rate (HR) \<40 beats per minute (bpm)\], arrhythmia, or urticaria due to lidocaine and dexmedetomidine infusion during the surgery

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Intravenous saline, dexmedetomidine and lidocaine (Type: EXPERIMENTAL): None
- Intravenous saline, dexmedetomidine, lidocaine and combination (Type: EXPERIMENTAL): None
- Intravenous saline,dexmedetomidine plus lidocaine (Type: EXPERIMENTAL): None
- Intravenous saline, dexmedetomidine combined with lidocaine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histological or cytological diagnosis of SCLC~* Limited disease (LD) or Extensive disease (ED) at time of study entry~* Recurrent or progressive SCLC ≥ 90 days of duration of response for firstline therapy~* Measurable disease defined by RECIST criteria~* ECOG Performance Status of 0, 1, or 2~* Life expectancy ≥ 3 months~* Adequate bone marrow, Renal, Hepatic reserve:~absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/mm3 platelet count ≥ 100,000 cells/ mm3 hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 mm3 Alanine aminotransferase (ALT) and aspartate aminotransferase(AST) ≤ 2.0 X ULN Alkaline Phosphatase (ALP) ≤ 2.0 X ULN Serum creatinine ≤ 1.5mg/dL or calculated creatinine clearance \> 60mL/min~- Signed a written informed consent~Exclusion Criteria:~* Active infection~* Symptomatic brain lesion~* Any other type of cancer during the previous 5 years~* Severe concurrent diseases~* Prior anticancer therapy within 4 weeks before enroll~* Active pregnancy test and Pregnant or nursing women~* Participation in any investigational drug study within 28 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belotecan (Type: EXPERIMENTAL): Camtobell Injection
- Topotecan (Type: ACTIVE_COMPARATOR): Hycamtin Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete